Living Cell Technologies Stock Performance
| LVCLF Stock | USD 0 0 166.67% |
Living Cell holds a performance score of 10 on a scale of zero to a hundred. The company secures a Beta (Market Risk) of 3.62, which conveys a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Living Cell will likely underperform. Use Living Cell Technologies potential upside and the relationship between the skewness and relative strength index , to analyze future returns on Living Cell Technologies.
Risk-Adjusted Performance
OK
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Living Cell Technologies are ranked lower than 10 (%) of all global equities and portfolios over the last 90 days. Despite nearly unfluctuating essential indicators, Living Cell reported solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 1.6 M | |
| Total Cashflows From Investing Activities | 39.5 K |
Living |
Living Cell Relative Risk vs. Return Landscape
If you would invest 0.51 in Living Cell Technologies on December 25, 2024 and sell it today you would lose (0.11) from holding Living Cell Technologies or give up 21.57% of portfolio value over 90 days. Living Cell Technologies is currently producing 6.1634% returns and takes up 47.9229% volatility of returns over 90 trading days. Put another way, most equities are less risky on the basis of their return distribution than Living, and majority of traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Living Cell Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Living Cell's investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Living Cell Technologies, and traders can use it to determine the average amount a Living Cell's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1286
| Best Portfolio | Best Equity | LVCLF | ||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 47.92 actual daily | 96 96% of assets are less volatile |
Expected Return
| 4.96 actual daily | 96 96% of assets have lower returns |
Risk-Adjusted Return
| 0.13 actual daily | 10 90% of assets perform better |
Based on monthly moving average Living Cell is performing at about 10% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Living Cell by adding it to a well-diversified portfolio.
Living Cell Fundamentals Growth
Living Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Living Cell, and Living Cell fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Living Pink Sheet performance.
| Return On Equity | -0.72 | |||
| Return On Asset | -0.31 | |||
| Operating Margin | (428.70) % | |||
| Current Valuation | 12.53 M | |||
| Shares Outstanding | 1.29 B | |||
| Price To Earning | (31.67) X | |||
| Price To Book | 6.96 X | |||
| Price To Sales | 5,587 X | |||
| Revenue | 3.4 K | |||
| EBITDA | (2.38 M) | |||
| Cash And Equivalents | 4.24 M | |||
| Total Debt | 228.44 K | |||
| Debt To Equity | 0.10 % | |||
| Book Value Per Share | 0 X | |||
| Cash Flow From Operations | (2.04 M) | |||
| Earnings Per Share | (0) X | |||
| Total Asset | 4.27 M | |||
| Retained Earnings | (67 M) | |||
| Current Asset | 6 M | |||
| Current Liabilities | 1000 K | |||
About Living Cell Performance
By analyzing Living Cell's fundamental ratios, stakeholders can gain valuable insights into Living Cell's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Living Cell has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Living Cell has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Living Cell Technologies Limited, a biotechnology company, discovers, develops, and commercializes regenerative treatments that use naturally occurring cells to restore functions in Australia and New Zealand. The company was founded in 1987 and is based in Sydney, Australia. Living Cell operates under Biotechnology classification in the United States and is traded on OTC Exchange.Things to note about Living Cell Technologies performance evaluation
Checking the ongoing alerts about Living Cell for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Living Cell Technologies help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Living Cell is way too risky over 90 days horizon | |
| Living Cell has some characteristics of a very speculative penny stock | |
| Living Cell appears to be risky and price may revert if volatility continues | |
| The company reported the revenue of 3.4 K. Net Loss for the year was (1.96 M) with profit before overhead, payroll, taxes, and interest of 3.4 K. | |
| Living Cell Technologies has accumulated about 4.24 M in cash with (2.04 M) of positive cash flow from operations. | |
| Roughly 34.0% of the company outstanding shares are owned by corporate insiders |
- Analyzing Living Cell's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Living Cell's stock is overvalued or undervalued compared to its peers.
- Examining Living Cell's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Living Cell's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Living Cell's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Living Cell's pink sheet. These opinions can provide insight into Living Cell's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Living Pink Sheet analysis
When running Living Cell's price analysis, check to measure Living Cell's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Living Cell is operating at the current time. Most of Living Cell's value examination focuses on studying past and present price action to predict the probability of Living Cell's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Living Cell's price. Additionally, you may evaluate how the addition of Living Cell to your portfolios can decrease your overall portfolio volatility.
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Equity Valuation Check real value of public entities based on technical and fundamental data |